贝伐单抗联合化学药物治疗耐药晚期非小细胞肺癌

目的：探讨贝伐单抗联合化学药物治疗耐药晚期非小细胞肺癌（non—smallcelllung ca11cer，NSCLC）的疗效及安全性。方法：对2011年1月至2012年9月收治的9例耐药晚期NSCLC患者给予贝伐单抗联合化疗治疗，其中多西他赛联合贝伐单抗3例、培美曲塞二钠联合贝伐单抗5例、紫杉醇联合贝伐单抗1例。每例患者均完成2个周期以上治疗，观察其近期疗效及安全性。结果：9例患者中，3例部分缓解。无进展生存期2～12个月，总生存期4～16个月。主要不良反应有骨髓抑制、下肢静脉血栓、充血性心力衰竭、血压升高、消化道反应以及脱发。结论：贝伐单抗联合化疗治疗耐药晚期NSCLC取得较好疗效，毒性可以耐受。

Combination of bevacizumab with chemotherapy for treating drug-resistant advanced non-small cell lung cancer

Objective： To evaluate efficacy and safety of chemotherapy combined with bevacizumab for drug-resistant advanced non-small cell lung cancer （NSCLC）. Methods： Nine patients with resistant advanced NSCLC were treated by bevacizumab combined with chemotherapy from Jan. 2011 to Sep. 2012, whereas 3, S or 1 patient was chosen for chemotherapy with docetaxel, pemetrexed disodium or paditaxel, respectively Each patient had completed 2 or more treatment cycles. The clinical efficacy and safety of the treatment were evaluated according to RECIST 1.1. Results： Three of 9 patients showed partial remission. The progression-free survival varied from 2 to 12 months, and overall survival varied from 4 to16 months. The main side-effects were bone marrow inhibition, lower limb vein thrombus, congestive heart failure, hypertension, gastrointestinal tract reaction and alopecia. Conclusion： Combination of bevacizumab with chemotherapy is an alternative treatment for drug-resistant advanced NSCLC and the toxicity can be tolerated.